CRL Charles River Laboratories International, Inc. Common Stock
$288,77
Prezzo · Ago 18, 2026
Fondamentali al Ago 5, 2026
Intervallo 52 sett.
$144–$289
100% of range
Rating Analisti
BUY
22 analysts
Prezzo Obiettivo
$281
P/E (TTM)
-99.2
ROE
-4.4%
Margine di Profitto Netto
-3.6%
Informazioni su Charles River Laboratories International, Inc. Common Stock Panoramica della società da Wikipedia
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Leggi di più
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
CRL Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$288.77
Capitalizzazione di Mercato
$14.21B
P/E (TTM)
-99.2
EPS (TTM)
$-2.91
Ricavi (TTM)
$4.02B
Rendimento div.
—
ROE
-4.4%
D/E Debito/Patrimonio
0.0
Intervallo 52 sett.
$144 – $289
CRL Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$4.02B
2016-12-31
→
2025-12-27
EPS
$-2.91
2016-12-31
→
2025-12-27
Flusso di cassa libero
$518M
2016-12-31
→
2025-12-27
Margini
-3.6%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
CRL
Mediana dei peer
P/E (TTM)
-99.2
39.9
P/S (TTM)
3.5
5.6
P/B
4.5
4.1
EV / EBITDA
32.7
—
Price / FCF (Prezzo / FCF)
27.4
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
CRL
Mediana dei peer
Operating Margin (Margine Operativo)
0.63%
—
Net Profit Margin (Margine di Profitto Netto)
-3.6%
11.7%
ROA
-2.0%
4.7%
ROE
-4.4%
8.5%
ROIC
1.1%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
CRL
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
0.0
15.3
Current Ratio (Rapporto corrente)
1.3
1.7
Quick Ratio
0.8
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
CRL
Mediana dei peer
Revenue YoY (Ricavi YoY)
-0.85%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
0.33%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
6.6%
—
EPS YoY
-97.8%
—
Net Income YoY (Utile Netto YoY)
-95.3%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
CRL
Mediana dei peer
CRL Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
22 analisti
- Acquisto forte 5 22,7%
- Compra 10 45,5%
- Mantieni 7 31,8%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
14 analisti · 2026-08-14
Mediana
$300.00
Media
$281.00
Ora
$288.77
Basso
$145.00
Alto
$318.00
Target mediano
$300.00
+3,9%
Target medio
$281.00
-2,7%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.21%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $3.02 | $2.76 | 0.26% |
| 31 Marzo 2026 | $2.06 | $1.96 | 0.10% |
| 31 Dicembre 2025 | $2.39 | $2.37 | 0.02% |
| 30 Settembre 2025 | $2.43 | $2.36 | 0.07% |
| 30 Giugno 2025 | $3.12 | $2.52 | 0.60% |
| 31 Marzo 2025 | $2.34 | $2.10 | 0.24% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| BIO | — | — | — | — | — | — |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 15
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Stato Patrimoniale 30
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Flusso di cassa 18
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Tassi di Crescita 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Conto Economico 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | -99,475,000 | 49,213,000 | 49,149,000 | 50,677,000 | -103,002,000 | 51,394,000 | 51,551,000 | 51,437,000 | 28,000 | 51,283,000 | 51,097,000 | -101,521,000 | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | -100,031,000 | 49,426,000 | 49,316,000 | 50,853,000 | -103,643,000 | 51,583,000 | 51,846,000 | 51,842,000 | -42,000 | 51,607,000 | 51,428,000 | -102,590,000 | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Stato Patrimoniale 28
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Flusso di cassa 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Redditività 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Valutazione (TTM) 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.04B | $4.02B | · | $4.03B | $4.05B | $4.03B | · | $4.07B | $4.12B | $4.13B | · | $4.11B | $3.91B | · | $3.77B | |
| Net Income TTM | $90M | $117M | · | $202M | $242M | $262M | · | $324M | $351M | $360M | · | $384M | $402M | · | $402M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | 117.9 | 67.4 | · | 37.2 | 32.4 | 31.9 | · | 32.7 | 31.2 | 39.3 | · | 26.2 | 25.8 | · | 23.9 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | · | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| P / FCF | · | -516.9 | · | · | · | 68.0 | · | · | · | 275.0 | · | · | · | · | · | |
| EV / EBITDA | 54.0 | 40.0 | · | 32.4 | 32.8 | 38.0 | · | 48.3 | 44.1 | 64.5 | · | 43.0 | · | · | 41.4 | |
| EV / FCF | · | -504.4 | · | · | · | 65.9 | · | · | · | 268.6 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.5 | 3.3 | · | 2.4 | · | · | 2.5 | |
| Earnings Yield | 0.85% | 1.5% | · | 2.7% | 3.1% | 3.1% | · | 3.1% | 3.2% | 2.5% | · | 3.8% | 3.9% | · | 4.2% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Ricavi | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Margine Operativo % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Utile netto | $-144M | $22M | $475M | $486M | $391M |
| EPS Diluito | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Stato Patrimoniale
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Rapporto corrente | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
Flusso di cassa
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $518M | $502M | $365M | $295M | $532M |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 616 filer · $7.8B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 82 (-1 vs trimestre precedente) | 59 (-23 vs trimestre precedente) | 180 (-11 vs trimestre precedente) | 201 (+15 vs trimestre precedente) | +5.0M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| FMR LLC | $737.350.307 | 3.251.247 | 9,42% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.227.026 | 3.149.288 | 9,12% | Azioni |
| HARRIS ASSOCIATES L P | $508.269.048 | 2.241.144 | 6,49% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.427.927 | 2.210.979 | 6,40% | Azioni |
| STATE STREET CORP | $422.800.968 | 1.864.284 | 5,40% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $348.883.077 | 1.538.354 | 4,46% | Azioni |
| CITADEL ADVISORS LLC | $270.696.771 | 1.193.601 | 3,46% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $259.130.041 | 1.144.937 | 3,31% | Azioni |
| EARNEST PARTNERS LLC | $254.007.295 | 1.120.011 | 3,24% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $223.361.616 | 984.883 | 2,85% | Azioni |
| AMERIPRISE FINANCIAL INC | $192.886.814 | 850.503 | 2,46% | Azioni |
| NEUBERGER BERMAN GROUP LLC | $192.182.793 | 847.488 | 2,45% | Azioni |
| Clearbridge Investments, LLC | $177.185.527 | 781.276 | 2,26% | Azioni |
| COOKE & BIELER LP | $171.369.328 | 755.630 | 2,19% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $150.762.735 | 664.768 | 1,93% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $110.324.717 | 486.462 | 1,41% | Azioni |
| BANK OF AMERICA CORP /DE/ | $104.921.899 | 462.639 | 1,34% | Azioni |
| Gotham Asset Management, LLC | $98.233.181 | 433.146 | 1,25% | Azioni |
| Amundi | $93.528.650 | 412.402 | 1,19% | Azioni |
| NORGES BANK | $83.921.372 | 370.040 | 1,07% | Azioni |
| MARSHALL WACE, LLP | $76.947.125 | 339.288 | 0,98% | Azioni |
| Iron Triangle Partners LP | $75.748.141 | 379.728 | 0,97% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $64.615.913 | 374.585 | 0,83% | Azioni |
| SNYDER CAPITAL MANAGEMENT L P | $63.899.443 | 281.756 | 0,82% | Azioni |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63.174.169 | 278.558 | 0,81% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $63.095.473 | 278.211 | 0,81% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $61.384.115 | 270.665 | 0,78% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $60.523.448 | 266.870 | 0,77% | Azioni |
| GOLDMAN SACHS GROUP INC | $57.319.812 | 252.744 | 0,73% | Azioni |
| Meridiem Capital Partners LP | $56.012.367 | 246.979 | 0,72% | Azioni |
| Alyeska Investment Group, L.P. | $53.295.650 | 235.000 | 0,68% | Azioni |
| Quantinno Capital Management LP | $49.020.824 | 216.150 | 0,63% | Azioni |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $48.415.129 | 213.480 | 0,62% | Azioni |
| Boston Trust Walden Corp | $46.506.918 | 205.066 | 0,59% | Azioni |
| Burgundy Asset Management Ltd. | $45.453.909 | 278.329 | 0,58% | Azioni |
| SRS Investment Management, LLC | $42.496.817 | 187.384 | 0,54% | Azioni |
| LOOMIS SAYLES & CO L P | $38.517.487 | 169.838 | 0,49% | Azioni |
| JONES FINANCIAL COMPANIES LLLP | $37.184.513 | 172.350 | 0,47% | Azioni |
| PERCEPTIVE ADVISORS LLC | $31.750.600 | 140.000 | 0,41% | Azioni |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $30.389.860 | 134.000 | 0,39% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $29.879.583 | 131.750 | 0,38% | Azioni |
| BlackRock, Inc. | $29.025.945 | 127.986 | 0,37% | Azioni |
| PICTON MAHONEY ASSET MANAGEMENT | $26.340.305 | 116.144 | 0,34% | Azioni |
| FIL Ltd | $25.184.576 | 111.048 | 0,32% | Azioni |
| Candriam S.C.A. | $23.824.478 | 105.152 | 0,30% | Azioni |
| Clark Capital Management Group, Inc. | $23.010.567 | 101.462 | 0,29% | Azioni |
| Vanguard Global Advisers, LLC | $22.453.344 | 99.005 | 0,29% | Azioni |
| Swiss National Bank | $22.452.210 | 99.000 | 0,29% | Azioni |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $20.491.384 | 90.354 | 0,26% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $20.280.546 | 89.424 | 0,26% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.730.730 | 87.000 | 0,25% | Opzione Call |
| NOMURA HOLDINGS INC | $19.672.672 | 86.744 | 0,25% | Azioni |
| RHUMBLINE ADVISERS | $19.484.825 | 85.916 | 0,25% | Azioni |
| Ilex Capital Partners (UK) LLP | $18.413.760 | 81.193 | 0,24% | Azioni |
| Aristotle Capital Boston, LLC | $18.273.438 | 80.574 | 0,23% | Azioni |
| CITADEL ADVISORS LLC | $17.485.509 | 77.100 | 0,22% | Opzione Call |
| NICHOLAS COMPANY, INC. | $16.305.067 | 71.895 | 0,21% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $15.172.024 | 66.899 | 0,19% | Azioni |
| Mitsubishi UFJ Asset Management Co., Ltd. | $15.164.087 | 66.864 | 0,19% | Azioni |
| Ranger Investment Management, L.P. | $15.009.416 | 66.182 | 0,19% | Azioni |
| California Public Employees Retirement System | $14.670.818 | 64.689 | 0,19% | Azioni |
| Assenagon Asset Management S.A. | $14.020.385 | 61.821 | 0,18% | Azioni |
| ASSETMARK, INC | $13.939.194 | 61.463 | 0,18% | Azioni |
| Rhenman & Partners Asset Management AB | $12.972.388 | 57.200 | 0,17% | Azioni |
| RIVERBRIDGE PARTNERS LLC | $12.859.587 | 56.703 | 0,16% | Azioni |
| TD Asset Management Inc | $12.854.230 | 56.679 | 0,16% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12.836.314 | 56.600 | 0,16% | Opzione Put |
| Laurus Investment Counsel Inc. | $12.365.663 | 71.685 | 0,16% | Azioni |
| KING LUTHER CAPITAL MANAGEMENT CORP | $12.204.023 | 53.812 | 0,16% | Azioni |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $11.552.133 | 50.938 | 0,15% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10.732.081 | 47.278 | 0,14% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $10.506.727 | 46.328 | 0,13% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $10.472.482 | 46.177 | 0,13% | Azioni |
| KENNEDY CAPITAL MANAGEMENT LLC | $9.914.950 | 43.719 | 0,13% | Azioni |
| BARCLAYS PLC | $9.909.816 | 43.696 | 0,13% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $9.827.670 | 56.972 | 0,13% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9.382.529 | 41.371 | 0,12% | Azioni |
| Park West Asset Management LLC | $9.343.748 | 41.200 | 0,12% | Azioni |
| State of Tennessee, Department of Treasury | $8.457.000 | 37.290 | 0,11% | Azioni |
| J.P. Marvel Investment Advisors, LLC | $8.456.092 | 37.286 | 0,11% | Azioni |
| CASTLEARK MANAGEMENT LLC | $8.174.646 | 36.045 | 0,10% | Azioni |
| JANE STREET GROUP, LLC | $7.869.613 | 34.700 | 0,10% | Opzione Call |
| Pine Ridge Advisers LLC | $7.710.860 | 34.000 | 0,10% | Azioni |
| PRUDENTIAL FINANCIAL INC | $7.346.635 | 32.394 | 0,09% | Azioni |
| Capricorn Fund Managers Ltd | $7.092.630 | 31.274 | 0,09% | Azioni |
| STATE OF WISCONSIN INVESTMENT BOARD | $7.000.554 | 30.868 | 0,09% | Azioni |
| FIRST TRUST ADVISORS LP | $6.951.290 | 30.651 | 0,09% | Azioni |
| Caption Management, LLC | $6.803.700 | 30.000 | 0,09% | Opzione Put |
| Engineers Gate Manager LP | $6.637.463 | 29.267 | 0,08% | Azioni |
| LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE | $6.351.027 | 28.004 | 0,08% | Azioni |
| Midwest Trust Co | $6.091.126 | 26.858 | 0,08% | Azioni |
| VAN ECK ASSOCIATES CORP | $5.942.578 | 26.203 | 0,08% | Azioni |
| SEI INVESTMENTS CO | $5.929.630 | 26.150 | 0,08% | Azioni |
| Sendero Wealth Management, LLC | $5.909.468 | 26.057 | 0,08% | Azioni |
| 13D Management LLC | $5.851.182 | 25.800 | 0,07% | Azioni |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $5.500.853 | 31.889 | 0,07% | Azioni |
| D. E. Shaw & Co., Inc. | $5.462.691 | 24.087 | 0,07% | Azioni |
| INVESTMENT HOUSE LLC | $5.447.042 | 24.018 | 0,07% | Azioni |
| LPL Financial LLC | $5.409.169 | 23.851 | 0,07% | Azioni |
| LRT Capital Management, LLC | $5.348.842 | 23.585 | 0,07% | Azioni |
Insider aziendali 57 insider · 21 dirigenti · 27 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | 29 Maggio 2026 A | 27.752 | 0 | 0 | $0 |
| Flavia Pease | Corporate Executive VP & CFO | 31 Maggio 2025 F | 17.297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 03 Marzo 2022 M | 25.819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 Luglio 2018 M | 17.155 | 0 | 0 | $0 |
| Mark Mintz | EVP, Chief Information Officer | 31 Maggio 2026 F | 9.546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 07 Novembre 2024 G | 23.337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 01 Giugno 2020 A | 3.171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 Maggio 2020 A | 224.478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 01 Ottobre 2016 F | 5.599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 02 Marzo 2016 S | 11.034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 Febbraio 2015 M | 14.094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 Agosto 2010 F | 74.390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 Febbraio 2010 A | 31.897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 Agosto 2007 F | 37.109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 Giugno 2007 M | 11.750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 01 Maggio 2007 A | 6.262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 02 Aprile 2007 A | 11.500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 02 Aprile 2007 F | 12.713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 Febbraio 2007 A | 12.710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 Febbraio 2006 S | 16.134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 Dicembre 2004 M | 8.000 | 0 | 0 | $0 |
| Steven Barg | Direttore | 02 Giugno 2026 A | 3.287 | 0 | 0 | $0 |
| Nancy C Andrews | Direttore | 12 Maggio 2026 G | 3.964 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Direttore | 08 Maggio 2026 A | 4.563 | 0 | 0 | $0 |
| George Llado | Direttore | 08 Maggio 2026 A | 6.702 | 0 | 0 | $0 |
| Abraham Ceesay | Direttore | 08 Maggio 2026 A | 2.384 | 0 | 0 | $0 |
| Mark J Enyedy | Direttore | 08 Maggio 2026 A | 2.384 | 0 | 0 | $0 |
| Paul W Graves | Direttore | 08 Maggio 2026 A | 2.384 | 0 | 0 | $0 |
| Craig B. Thompson | Direttore | 08 Maggio 2026 A | 3.851 | 0 | 0 | $0 |
| Martin Mackay | Direttore | 08 Maggio 2026 A | 17.137 | 0 | 0 | $0 |
| Virginia M Wilson | Direttore | 08 Maggio 2026 A | 6.349 | 0 | 0 | $0 |
| George Massaro | Direttore | 15 Maggio 2025 S | 5.575 | 0 | 0 | $0 |
| Richard F Wallman | Direttore | 07 Novembre 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Direttore | 13 Maggio 2024 A | 7.894 | 0 | 0 | $0 |
| Robert J Bertolini | Direttore | 13 Maggio 2024 A | 32.802 | 0 | 0 | $0 |
| Richard C Reese | Direttore | 15 Maggio 2023 A | 65.541 | 0 | 0 | $0 |
| George M Milne JR | Direttore | 07 Maggio 2021 A | 29.079 | 0 | 0 | $0 |
| Stephen D Chubb | Direttore | 23 Febbraio 2021 M | 40.529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Direttore | 22 Maggio 2019 A | 3.886 | 0 | 0 | $0 |
| William Waltrip | Direttore | 05 Dicembre 2012 S | 21.830 | 0 | 0 | $0 |
| Samuel O Thier MD | Direttore | 09 Maggio 2012 A | 18.230 | 0 | 0 | $0 |
| Douglas E Rogers | Direttore | 07 Maggio 2010 A | 12.859 | 0 | 0 | $0 |
| Nancy T Chang | Direttore | 07 Maggio 2010 A | 31.010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Direttore | 13 Febbraio 2006 A | — | 0 | 0 | $0 |
| Walter S Nimmo | Direttore | 25 Febbraio 2005 S | 149.447 | 0 | 0 | $0 |
| John Urquhart | Direttore | 17 Febbraio 2005 A | 11.738 | 0 | 0 | $0 |
| Louise S Mccrary | Direttore | 17 Febbraio 2005 A | — | 0 | 0 | $0 |
| Robert Cawthorn | Direttore | 02 Giugno 2004 G | 278.600 | 0 | 0 | $0 |
| Shannon M Parisotto | — | 11 Agosto 2026 M | 4.807 | 0 | 2 | $-2.365.755 |
| Birgit Girshick | — | 11 Agosto 2026 M | 36.013 | 0 | 1 | $-1.819.350 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 6 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 depositi | 04 Agosto 2011 | — | Deposito iniziale | — | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 depositi | 09 Febbraio 2011 | — | Deposito iniziale | — | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 depositi | 07 Dicembre 2010 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 16 Giugno 2010 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 07 Giugno 2010 | — | Deposito iniziale | Investimento passivo | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 05 Maggio 2010 | — | Deposito iniziale | Campagna per il consiglio di amministrazione | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 135 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 2,18% | 63.652 SH | 08 Agosto 2026 | Giornaliero |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,49% | 4.749 NS | 30 Aprile 2026 | N-PORT |
| EPSB · Harbor ETF Trust | 1,33% | 370 NS | 30 Aprile 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 1,18% | 41.597 SH | 08 Agosto 2026 | Giornaliero |
| EPMV · Harbor ETF Trust | 1,09% | 291 NS | 30 Aprile 2026 | N-PORT |
| IBB · iShares Trust | 0,97% | 349.491 SH | 08 Agosto 2026 | Giornaliero |
| EPSV · Harbor ETF Trust | 0,90% | 270 NS | 30 Aprile 2026 | N-PORT |
| TAX · EA Series Trust | 0,80% | 1.131 NS | 29 Maggio 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,66% | 612 NS | 30 Aprile 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,50% | 2.356 NS | 30 Aprile 2026 | N-PORT |
| ISCV · iShares Trust | 0,40% | 10.497 SH | 08 Agosto 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,38% | 11.925 NS | 30 Aprile 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,38% | 25.401 SH | 08 Agosto 2026 | Giornaliero |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | 0,36% | 1.145.000 PA | 08 Agosto 2026 | Giornaliero |
| IQSM · New York Life Investments ETF Trust | 0,33% | 6.161 NS | 30 Aprile 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,29% | 22.440 NS | 30 Aprile 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,27% | 996.151 SH | 08 Agosto 2026 | Giornaliero |
| DFAT · Dimensional ETF Trust | 0,26% | 212.321 NS | 30 Aprile 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701.498 SH | 08 Agosto 2026 | Giornaliero |
| ESML · iShares Trust | 0,23% | 24.979 SH | 08 Agosto 2026 | Giornaliero |
| BKMC · BNY Mellon ETF Trust | 0,22% | 8.115 NS | 30 Aprile 2026 | N-PORT |
| IYH · iShares Trust | 0,21% | 29.370 SH | 08 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | 0,20% | 2.125 SH | 08 Agosto 2026 | Giornaliero |
| SMMD · iShares Trust | 0,17% | 24.455 SH | 08 Agosto 2026 | Giornaliero |
| FSMD · FIDELITY COVINGTON TRUST | 0,17% | 24.528 NS | 30 Aprile 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,17% | 133.341 NS | 31 Maggio 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,16% | 138.243 NS | 30 Aprile 2026 | N-PORT |
| IXJ · iShares Trust | 0,16% | 25.598 SH | 08 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,16% | 148.331 SH | 08 Agosto 2026 | Giornaliero |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 18.369 NS | 30 Aprile 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,15% | 6.079 NS | 31 Maggio 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 6.018 SH | 08 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,13% | 22.674 NS | 30 Aprile 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,13% | 59.338 NS | 30 Aprile 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1.102.914 SH | 08 Agosto 2026 | Giornaliero |
| VGMS · VANGUARD MALVERN FUNDS | 0,13% | 315.000 PA | 08 Agosto 2026 | Giornaliero |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,13% | 4.072 SH | 08 Agosto 2026 | Giornaliero |
| RXL · ProShares Trust | 0,13% | 513 NS | 31 Maggio 2026 | N-PORT |
| IWS · iShares Trust | 0,13% | 74.284 SH | 08 Agosto 2026 | Giornaliero |
| REVS · Columbia ETF Trust I | 0,12% | 2.082 NS | 30 Aprile 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,12% | 982 NS | 30 Aprile 2026 | N-PORT |
| SMLF · iShares Trust | 0,12% | 18.532 SH | 08 Agosto 2026 | Giornaliero |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 3.280 NS | 30 Aprile 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,11% | 1.032 NS | 30 Aprile 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 199.595 SH | 08 Agosto 2026 | Giornaliero |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,09% | 1.986 NS | 31 Maggio 2026 | N-PORT |
| IEUS · iShares Trust | 0,09% | 4.951 SH | 08 Agosto 2026 | Giornaliero |
| XOEF · iShares Trust | 0,07% | 61 SH | 08 Agosto 2026 | Giornaliero |
| VSDB · VANGUARD MALVERN FUNDS | 0,07% | 635.000 PA | 08 Agosto 2026 | Giornaliero |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 5.261 NS | 30 Aprile 2026 | N-PORT |